Spero Therapeutics, Inc.
Bear Case (25th pct.)
32.5% vs price
Base Case (Median)
48.3% vs price
Bull Case (75th pct.)
93.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.84 | -29.9% | High (40%) |
| PE Comparable | $2.45 | 104.0% | Medium (25%) |
| Graham Number | $1.61 | 34.6% | Medium (40%) |
| EV/EBITDA | $1.58 | 31.4% | Medium (20%) |
| EV/FCF | $6.99 | 482.5% | Medium (20%) |
| Earnings Power Value | $1.94 | 61.3% | Medium (50%) |
Based on 6 out of 8 methods, SPRO appears undervalued at the current price of $1.20. The base case fair value of $1.78 implies 48.3% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.